D2E7 ( DrugBank: - )
1 disease
| 告示番号 | 疾患名（ページ内リンク） | 臨床試験数 |
|---|---|---|
| 46 | 悪性関節リウマチ | 10 |
46. 悪性関節リウマチ
臨床試験数 : 4,356 / 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2019-001793-28-NL (EUCTR) | 05/11/2019 | 05/11/2019 | Adalimumab dose reduction aiming low drug levels with control of disease activity (ADDORA-LOW) | Adalimumab dose reduction aiming low serum concentration with control of disease activity (ADDORA-LOW) : a single blind, non-inferiority, randomised clinical trial - ADDORA-Low | Rheumatoid arthritis;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Trade Name: Humira, Hulio, Amgevita, Hyrimoz, Idacio, Imraldi Product Name: Adalimumab Product Code: D2E7 INN or Proposed INN: ADALIMUMAB | Reade | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 89 | Phase 4 | Netherlands | ||
| 2 | EUCTR2019-001554-25-NL (EUCTR) | 29/10/2019 | 29/10/2019 | Adalimumab dose optimization in rheumatoid arthritis using drugconcentration in blood (ADDORA): multi-center open label randomizedcontrolled trail | Adalimumab dose optimization in rheumatoid arthritis using therapeuticdrug monitoring (ADDORA): multi-center open label randomized controlledtrail - ADalimumab Dose Optimization in Rheumatoid Arthritis using (ADDORA) | Rheumatoid arthritis;Therapeutic area: Diseases [C] - Immune System Diseases [C20] | Trade Name: Humira, Hulio, Amgevita, Hyrimoz, Idacio, Imraldi Product Name: Adalimumab Product Code: D2E7 INN or Proposed INN: ADALIMUMAB | Reade | NULL | Authorised-recruitment may be ongoing or finished | Female: yes Male: yes | 267 | Phase 1;Phase 4 | Netherlands | ||
| 3 | NCT00235872 (ClinicalTrials.gov) | August 2004 | 7/10/2005 | Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis | Open-Label Continuous Administration Study With Adalimumab (D2E7) in Subjects With Rheumatoid Arthritis | Rheumatoid Arthritis | Biological: adalimumab | Abbott | Abbott Japan Co.,Ltd;Eisai Co., Ltd. | Completed | 20 Years | N/A | All | 309 | Phase 3 | Japan |
| 4 | NCT00649545 (ClinicalTrials.gov) | July 2003 | 27/3/2008 | Study of the Human Anti-TNF Monoclonal Antibody in Patients With Active Rheumatoid Arthritis | A Multi-Center Study of the Safety and Efficacy of Human Anti-TNF Monoclonal Antibody Adalimumab (D2E7) in Patients With Active Rheumatoid Arthritis | Rheumatoid Arthritis | Biological: adalimumab | Abbott | NULL | Approved for marketing | 18 Years | N/A | Both | N/A | NULL | |
| 5 | NCT00235833 (ClinicalTrials.gov) | June 2003 | 7/10/2005 | Adalimumab in Adult Japanese Subjects With Rheumatoid Arthritis | Long-term Continuously Repeated Dose Study of Adalimumab (D2E7) in Patients With Rheumatoid Arthritis | Rheumatoid Arthritis | Biological: adalimumab | Abbott | Abbott Japan Co.,Ltd;Eisai Co., Ltd. | Completed | 20 Years | N/A | All | 25 | Phase 2 | Japan |
| 6 | NCT00234845 (ClinicalTrials.gov) | March 2003 | 13/9/2005 | Adalimumab in Combination With Methotrexate vs Methotrexate Alone in Early Rheumatoid Arthritis | A Multi-Centre Randomized, Double-Blind Study Comparing Adalimumab (D2E7) Plus Methotrexate With Placebo Plus Methotrexate on Work Disability in Subjects With Early Rheumatoid Arthritis | Rheumatoid Arthritis | Drug: adalimumab;Drug: methotrexate | Abbott | NULL | Completed | 18 Years | N/A | Both | 148 | Phase 3 | United States |
| 7 | NCT00049751 (ClinicalTrials.gov) | September 2002 | 13/11/2002 | Study of Human Anti-TNF Monoclonal Antibody D2E7 in Subjects With Active Rheumatoid Arthritis | A Multicenter Study of the Safety of Human Anti-TNF Monoclonal Antibody D2E7 in Subjects With Active Rheumatoid Arthritis | Rheumatoid Arthritis | Drug: Adalimumab | Abbott | NULL | Completed | 18 Years | N/A | Both | 3000 | Phase 3 | United States |
| 8 | NCT00448383 (ClinicalTrials.gov) | September 2002 | 14/3/2007 | A Study to Assess the Safety and Efficacy of Adalimumab When Added to Inadequate Standard Anti-Rheumatic Therapy in Patients With Active Rheumatoid Arthritis | An Open-Label, Multi-Center Study to Assess the Safety and Efficacy of the Fully Human Anti-TNF-a Monoclonal Antibody Adalimumab (D2E7) When Added to Inadequate Standard Anti-Rheumatic Therapy in Patients With Active Rheumatoid Arthritis | Rheumatoid Arthritis | Biological: adalimumab | Abbott | NULL | Completed | 18 Years | N/A | Both | 6610 | Phase 3 | NULL |
| 9 | NCT00195650 (ClinicalTrials.gov) | July 2000 | 13/9/2005 | Long Term Open Label Continuation Study | A Multi-Center Continuation Study of the Human Anti-TNF Antibody D2E7 Administered as a Subcutaneous Injection in Patients With Rheumatoid Arthritis | Rheumatoid Arthritis | Biological: Adalimumab | Abbott | NULL | Completed | 18 Years | N/A | All | 846 | Phase 3 | United States;Canada |
| 10 | NCT00233571 (ClinicalTrials.gov) | June 2000 | 13/9/2005 | A Long Term Roll-over Study to Investigate the Efficacy and Safety of Adalimumab Given Long-term to Patients With Rheumatoid Arthritis | A Multi-Centre Open Label Continuation Study With Subcutaneous D2E7 (Adalimumab) for Patients With Rheumatoid Arthritis Who Completed a Preceding Clinical Study With D2E7 (Adalimumab) | Rheumatoid Arthritis | Biological: Adalimumab 40 mg subcutaneous (SC) every other week (EOW) | Abbott | NULL | Completed | 18 Years | N/A | Both | 796 | Phase 3 | NULL |